Author

Brad S. Kahl

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

BACKGROUND High-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6, known as double-hit lymphoma, is a highly aggressive malignancy with poor outcomes after standard chemoimmunotherapy. We aimed to study whether the addition of the BCL2-inhibitor venetoclax to chemoimmunotherapy in patients with doub...

J. Abramson, S. Geyer, Sharmila Giri et al. · The Lancet Haematology · 0 citations

Open access Sep 2026

Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.

Histologic transformation (HT) is the leading of death in follicular lymphoma (FL), yet outcomes remain poorly defined due to small cohorts and heterogenous definitions. To characterize outcomes and treatment patterns in the rituximab era we analyzed 344 patients with an initial biopsy-confirmed FL diagnosis between 20...

J. Day, M. Larson, C. Casulo et al. · Haematologica · 0 citations